Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases
Research output: Contribution to journal › Review › Research › peer-review
Standard
Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases. / Thiele, Maja; Villesen, Ida Falk; Niu, Lili; Johansen, Stine; Sulek, Karolina; Nishijima, Suguru; Espen, Lore Van; Keller, Marisa; Israelsen, Mads; Suvitaival, Tommi; Zawadzki, Andressa de; Juel, Helene Bæk; Brol, Maximilian Joseph; Stinson, Sara Elizabeth; Huang, Yun; Silva, Maria Camilla Alvarez; Kuhn, Michael; Anastasiadou, Ema; Leeming, Diana Julie; Karsdal, Morten; Matthijnssens, Jelle; Arumugam, Manimozhiyan; Dalgaard, Louise Torp; Legido-Quigley, Cristina; Mann, Matthias; Trebicka, Jonel; Bork, Peer; Jensen, Lars Juhl; Hansen, Torben; Krag, Aleksander; MicrobLiver Consortium; GALAXY Consortium.
In: Journal of Hepatology, 2024.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases
AU - Thiele, Maja
AU - Villesen, Ida Falk
AU - Niu, Lili
AU - Johansen, Stine
AU - Sulek, Karolina
AU - Nishijima, Suguru
AU - Espen, Lore Van
AU - Keller, Marisa
AU - Israelsen, Mads
AU - Suvitaival, Tommi
AU - Zawadzki, Andressa de
AU - Juel, Helene Bæk
AU - Brol, Maximilian Joseph
AU - Stinson, Sara Elizabeth
AU - Huang, Yun
AU - Silva, Maria Camilla Alvarez
AU - Kuhn, Michael
AU - Anastasiadou, Ema
AU - Leeming, Diana Julie
AU - Karsdal, Morten
AU - Matthijnssens, Jelle
AU - Arumugam, Manimozhiyan
AU - Dalgaard, Louise Torp
AU - Legido-Quigley, Cristina
AU - Mann, Matthias
AU - Trebicka, Jonel
AU - Bork, Peer
AU - Jensen, Lars Juhl
AU - Hansen, Torben
AU - Krag, Aleksander
AU - MicrobLiver Consortium
AU - GALAXY Consortium
N1 - Publisher Copyright: © 2024 The Author(s)
PY - 2024
Y1 - 2024
N2 - The rising prevalence of liver diseases related to obesity and excessive use of alcohol is fuelling an increasing demand for accurate biomarkers aimed at community screening, diagnosis of steatohepatitis and significant fibrosis, monitoring, prognostication and prediction of treatment efficacy. Breakthroughs in omics methodologies and the power of bioinformatics have created an excellent opportunity to apply technological advances to clinical needs, for instance in the development of precision biomarkers for personalised medicine. Via omics technologies, biological processes from the genes to circulating protein, as well as the microbiome – including bacteria, viruses and fungi, can be investigated on an axis. However, there are important barriers to omics-based biomarker discovery and validation, including the use of semi-quantitative measurements from untargeted platforms, which may exhibit high analytical, inter- and intra-individual variance. Standardising methods and the need to validate them across diverse populations presents a challenge, partly due to disease complexity and the dynamic nature of biomarker expression at different disease stages. Lack of validity causes lost opportunities when studies fail to provide the knowledge needed for regulatory approvals, all of which contributes to a delayed translation of these discoveries into clinical practice. While no omics-based biomarkers have matured to clinical implementation, the extent of data generated has enabled the hypothesis-free discovery of a plethora of candidate biomarkers that warrant further validation. To explore the many opportunities of omics technologies, hepatologists need detailed knowledge of commonalities and differences between the various omics layers, and both the barriers to and advantages of these approaches.
AB - The rising prevalence of liver diseases related to obesity and excessive use of alcohol is fuelling an increasing demand for accurate biomarkers aimed at community screening, diagnosis of steatohepatitis and significant fibrosis, monitoring, prognostication and prediction of treatment efficacy. Breakthroughs in omics methodologies and the power of bioinformatics have created an excellent opportunity to apply technological advances to clinical needs, for instance in the development of precision biomarkers for personalised medicine. Via omics technologies, biological processes from the genes to circulating protein, as well as the microbiome – including bacteria, viruses and fungi, can be investigated on an axis. However, there are important barriers to omics-based biomarker discovery and validation, including the use of semi-quantitative measurements from untargeted platforms, which may exhibit high analytical, inter- and intra-individual variance. Standardising methods and the need to validate them across diverse populations presents a challenge, partly due to disease complexity and the dynamic nature of biomarker expression at different disease stages. Lack of validity causes lost opportunities when studies fail to provide the knowledge needed for regulatory approvals, all of which contributes to a delayed translation of these discoveries into clinical practice. While no omics-based biomarkers have matured to clinical implementation, the extent of data generated has enabled the hypothesis-free discovery of a plethora of candidate biomarkers that warrant further validation. To explore the many opportunities of omics technologies, hepatologists need detailed knowledge of commonalities and differences between the various omics layers, and both the barriers to and advantages of these approaches.
KW - genetics
KW - lipidomics
KW - metabolomics
KW - metagenomics
KW - metatranscriptomics
KW - microbiome
KW - Non-invasive test
KW - proteomics
KW - viromics
U2 - 10.1016/j.jhep.2024.03.035
DO - 10.1016/j.jhep.2024.03.035
M3 - Review
C2 - 38552880
AN - SCOPUS:85192503701
JO - Journal of Hepatology, Supplement
JF - Journal of Hepatology, Supplement
SN - 0169-5185
ER -
ID: 392456005